ArticleGeburtshilfe und Frauenheilkunde2018
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.
Article in Geburtshilfe und Frauenheilkunde, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Genetic evidence for causal effects of inflammatory protein factors on breast cancer.Discover oncology · 2025Article
- CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women.Cancer biomarkers : section A of Disease markers · 2022Article
- Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Breast care (Basel, Switzerland) · 2021Article
- Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design.Molecules (Basel, Switzerland) · 2021Article
- Article
- Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma.Archives of gynecology and obstetrics · 2020Article
- Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations ofReports of biochemistry & molecular biology · 2019Article
- Antitumoral Effect of Laurinterol on 3D Culture of Breast Cancer Explants.Marine drugs · 2019Article
- Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study.Breast care (Basel, Switzerland) · 2019Article
- Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.Geburtshilfe und Frauenheilkunde · 2019Article
- Mechanisms of Metastasis and Cell Mobility - The Role of Metabolism.Geburtshilfe und Frauenheilkunde · 2019Article
- Article
- [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes].Der Pathologe · 2018Review
- Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.Geburtshilfe und Frauenheilkunde · 2018Article
- Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.Geburtshilfe und Frauenheilkunde · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.